Welcome to our dedicated page for Primerica SEC filings (Ticker: PRI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking Primerica’s life-insurance reserves, commission payouts, and the size of its licensed-representative force can be daunting; the company’s annual report alone spans hundreds of pages packed with actuarial tables and deferred acquisition cost roll-forwards. If you have ever searched for “Primerica SEC filings explained simply” or tried to pinpoint the latest “Primerica quarterly earnings report 10-Q filing,” you know how quickly EDGAR becomes overwhelming. Digging through “Primerica insider trading Form 4 transactions” for clues about executive sentiment only adds to the complexity.
Stock Titan resolves this with AI-powered summaries that translate insurance jargon into clear language, turning “understanding Primerica SEC documents with AI” from aspiration into reality. Our engine highlights solvency ratios, segment revenue, and policy lapse trends and instantly flags “Primerica Form 4 insider transactions real-time,” so you never miss a key share purchase or sale. Even the “Primerica annual report 10-K simplified” arrives within moments of EDGAR release, annotated with plain-English explanations of reserve adjustments and capital requirements.
Use our platform to:
- Receive concise “Primerica earnings report filing analysis” minutes after each release.
- Monitor “Primerica executive stock transactions Form 4” alongside our risk-weighted scoring.
- Dive into “Primerica proxy statement executive compensation” tables without scanning 100+ pages.
- Get “Primerica 8-K material events explained” so you understand how reinsurance treaties or distributor agreements affect valuation.
Every filing type—10-K, 10-Q, 8-K, DEF 14A, S-8—is updated in real time and paired with expert commentary. Make informed decisions faster by converting dense disclosures into actionable insights.
Primerica, Inc. (PRI) filed a Form 144 notifying a proposed sale of 2,500 shares of common stock through Morgan Stanley Smith Barney on the NYSE with an indicated aggregate market value of $645,675.00. The shares were acquired as Restricted Stock Units on 03/01/2025 and the filing lists an approximate sale date of 08/12/2025. The filing also discloses a prior 10b5-1 sale of 2,500 shares on 06/13/2025 generating gross proceeds of $647,591.25. Outstanding shares are shown as 32,391,333, making the proposed block a very small percentage of the company.
Primerica Q2 2025 10-Q highlights
- Revenue inched up 0.3% YoY to $793.3 million; commissions & fees rose 14% while net premiums grew 3.6%.
- Pre-tax income from continuing ops fell 14% to $234.5 million; net income declined to $178.3 million (-15%) as prior-year results contained a one-off $50 million insurance recovery.
- Diluted EPS from continuing ops dropped to $5.40 (-11%); total diluted EPS unchanged by discontinued Senior Health unit, which caused a $208 million loss in Q2 2024.
- Segment performance: Term Life pre-tax profit +5% to $155.0 million; Investment & Savings Products +6% to $79.4 million; Corporate & Other near breakeven versus $50.2 million profit last year.
- Capital returns: 2Q buybacks of $127 million and dividends of $34 million reduced diluted share count 4% YoY to 32.9 million; YTD repurchases total $251 million.
- Balance sheet: Assets $14.83 b (+2% YTD); equity $2.31 b (+2%). Cash fell to $621 million after $329 million financing outflows. AOCI improved by $63 million YTD on discount-rate and FX movements.
- Liquidity & cash flow: Operating cash flow solid at $360 million versus $384 million YTD 2024; investing cash outflow $100 million driven by portfolio reinvestment.
Bottom line: Core franchises showed modest growth, but elevated expenses and loss of 2024’s non-recurring gain compressed margins. Shareholder payouts remain aggressive, sustaining mid-teens ROE.